R

Rhythm Pharmaceuticals
D

RYTM

59.910
USD
0.94
(1.59%)
Market Closed
Volume
7,442
EPS
-4
Div Yield
-
P/E
-14
Market Cap
3,681,893,004
OverviewSignalsIdeasNews
Related Instruments
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    C
    CRBP
    -0.950
    (-5.41%)
    16.610 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    P
    PRQR
    -0.13000
    (-3.28%)
    3.83000 USD
    Q
    QURE
    -0.55000
    (-8.14%)
    6.21000 USD
    R
    RARE
    -2.865
    (-6.02%)
    44.745 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    More
News

Title: Rhythm Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.